TNFRSF9 and neoplasm: These include trispecific constructs targeting multiple tumor antigens (to overcome heterogeneity or escape) or integrating costimulatory signals (e.g., targeting 4-1BB (CD137)) or cytokine moieties (e.g., IL-15) to provide synergistic effects by simultaneously addressing antigen escape and boosting immune activation or survival [24,25].